Search results for " progression"

showing 10 items of 1092 documents

HLA-C1 ligands are associated with increased susceptibility to systemic lupus erythematosus.

2017

Recently, the role of killer cell immunoglobulin-like receptor (KIR) in autoimmune diseases has received increasing attention. The present study was undertaken to determine the association of KIR genes and the human leukocytes antigen (HLA) ligands with Systemic Lupus Erythematosus (SLE) and accompanying oxidative stress. Presence or absence of 17 KIR and 5 HLA loci was performed using the polymerase chain reaction-sequence specific primer (PCR-SSP) method by case-control study. A total of 45 SLE patients, and 60 healthy controls, all of Sicilian descent, were enrolled. Plasma values of the anti-oxidant molecule Taurine were determined in all subjects by capillary electrophoresis UV detecti…

0301 basic medicineMaleTaurineTaurineCellSLEDiseasemedicine.disease_causechemistry.chemical_compound0302 clinical medicineReceptors KIRImmunology and AllergyLupus Erythematosus SystemicReceptorSicilyGeneral MedicineMiddle AgedKIRHLAmedicine.anatomical_structureDisease ProgressionFemaleCase-Control StudieHumanAdultNKImmunologyGenetic Association StudieHuman leukocyte antigenHLA-C Antigens03 medical and health sciencesYoung AdultAntigenmedicineHumansGeneGenetic Association StudiesSettore MED/04 - Patologia Generale030203 arthritis & rheumatologyHLA-C Antigenbusiness.industryOxidative StreSettore MED/16 - ReumatologiaOxidative Stress030104 developmental biologychemistryCase-Control StudiesImmunologybusinessOxidative stressHuman immunology
researchProduct

Homocysteine concentration in coronary artery disease: Influence of three common single nucleotide polymorphisms.

2017

Whether single nucleotide polymorphisms (SNPs) of homocysteine metabolism enzymes influence the rate of cardiovascular (CV) events in coronary artery disease (CAD) patients remains controversial.In this analysis, 1126 subjects from the AtheroGene study with CAD and 332 control subjects without known CAD were included. The following SNPs were investigated: methylentetrahydrofolate reductase (MTHFR-C667T), methionin synthetase (MS-D919G), and cystathionin beta synthetase (CBS-I278T). The endpoint was the combination of cardiovascular death, stroke, and non-fatal myocardial infarction (N = 286). The median follow-up time was 6.4 years. Kaplan-Meier curve analysis showed an increasing event rat…

0301 basic medicineMaleTime FactorsHomocysteineEndocrinology Diabetes and MetabolismMyocardial InfarctionMedicine (miscellaneous)Coronary Artery DiseaseKaplan-Meier Estimate030204 cardiovascular system & hematologyReductaseGastroenterology5-Methyltetrahydrofolate-Homocysteine S-MethyltransferaseCoronary artery diseasechemistry.chemical_compound0302 clinical medicineGene FrequencyRisk FactorsMyocardial infarctionStrokeHomocysteineGeneticsNutrition and DieteticsbiologyHomozygoteMiddle AgedStrokePhenotypeArea Under CurveDisease ProgressionFemaleCardiology and Cardiovascular Medicinemedicine.medical_specialtyHeterozygoteCystathionine beta-SynthaseSingle-nucleotide polymorphismPolymorphism Single NucleotideRisk Assessment03 medical and health sciencesPredictive Value of TestsInternal medicinemedicineHumansGenetic Predisposition to DiseaseGenetic Association StudiesMethylenetetrahydrofolate Reductase (NADPH2)AgedProportional Hazards ModelsChi-Square DistributionCurve analysismedicine.disease030104 developmental biologychemistryROC CurveMethylenetetrahydrofolate reductaseCase-Control Studiesbiology.proteinBiomarkersNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Ita…

2019

Background Rheumatoid arthritis (RA) is associated with an increased risk of morbidity and mortality, when compared with general population, largely due to enhanced atherosclerotic disease. In this work, we aimed at assessing both occurrence and predictive factors of subclinical and clinical atherosclerosis in RA. Methods From January 1, 2015, to December 31, 2015, consecutive participants with RA, admitted to Italian Rheumatology Units, were assessed in the GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) cohort. After that, those participants were followed up in a 3-year, prospective, observational study, assessing the occurrence of subclinical and clinical ather…

0301 basic medicineMaleTime Factorslcsh:Diseases of the musculoskeletal systemType 2 diabetesComorbidityArthritis Rheumatoid0302 clinical medicineProspective StudiesSubclinical infectionAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceAge FactorsType 2 diabetesMiddle AgedPrognosisCardiovascular diseaseSurvival RateCardiovascular diseasesItalyRheumatoid arthritisAtherosclerosiCohortDisease ProgressionFemaleResearch ArticleAdultmedicine.medical_specialtyRemissionPopulation03 medical and health sciencesYoung AdultAge DistributionSex FactorsInternal medicinemedicineHumansSex DistributionRheumatoid arthritiseducationRheumatoid arthritiAged030203 arthritis & rheumatologybusiness.industryAtherosclerosis; Cardiovascular diseases; Remission; Rheumatoid arthritis; Type 2 diabetesmedicine.diseaseAtherosclerosisRheumatologySettore MED/16 - Reumatologia030104 developmental biologyBlood pressurelcsh:RC925-935businessFollow-Up Studies
researchProduct

Mediterranean diet and knee osteoarthritis outcomes: A longitudinal cohort study.

2018

Objectives: Mediterranean diet has several beneficial effects on health, but data regarding the association between Mediterranean diet and knee osteoarthritis (OA) are limited mainly to cross-sectional studies. We investigated whether higher Mediterranean diet adherence is prospectively associated with lower risk of radiographic OA (ROA), radiographic symptomatic knee OA (SxOA) and pain worsening in North American people at high risk or having knee OA. Methods: Adherence to the Mediterranean diet was evaluated using a validated Mediterranean diet score (aMED), categorized in five categories (Q1 to Q5, higher values reflecting higher adherence to Mediterranean diet). Knee OA outcomes include…

0301 basic medicineMalemedicine.medical_specialtyMediterranean diet*Osteoarthritis initiative030209 endocrinology & metabolismOsteoarthritisCritical Care and Intensive Care MedicineLower riskDiet MediterraneanArticleknee osteoarthritisNew onset03 medical and health sciencessymbols.namesake0302 clinical medicine*Mediterranean diet*Knee osteoarthritis*PainInternal medicineMediterranean dietMedicineHumanspainPoisson regressionLongitudinal StudiesLongitudinal cohort030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryMiddle AgedOsteoarthritis Kneemedicine.disease*OsteoarthritisArthralgiaosteoarthritisagedKnee painOsteoarthritis InitiativeRelative risksymbolsDisease ProgressionosteoarthritiFemalemedicine.symptom*Agedbusiness
researchProduct

Lysosomal acid lipase deficiency: Expanding differential diagnosis.

2016

The differential diagnoses for metabolic liver diseases may be challenging in clinical settings, which represents a critical issue for disorders such as lysosomal acid lipase deficiency (LAL-D). LAL-D is caused by deficient activity of the LAL enzyme, resulting in the accumulation of cholesteryl esters and triglycerides throughout the body, predominately in the liver, spleen, gastrointestinal tract, and blood vessel walls. LAL-D is a progressive, multi-organ disease with early mortality and significant morbidity characterized by a combination of hepatic dysfunction and dyslipidemia. Evidence suggests LAL-D may be substantially underdiagnosed or misdiagnosed, which is critical given that dis…

0301 basic medicineMalemedicine.medical_specialtyPathologyAdolescentEndocrinology Diabetes and MetabolismDiseaseLysosomal acid lipase deficiencyBiochemistryGastroenterologyDiagnosis Differential03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineGeneticsmedicineLysosomal storage diseaseHumansChildMolecular BiologyTriglyceridesNiemann-Pick DiseasesGaucher Diseasebusiness.industryWolman DiseaseInfantEnzyme replacement therapySterol Esterasemedicine.diseaseClinical trial030104 developmental biologyEarly DiagnosisSebelipase alfaDisease Progression030211 gastroenterology & hepatologyFemaleCholesterol EstersDifferential diagnosisbusinessDyslipidemiaMolecular genetics and metabolism
researchProduct

On the role of cystatin C in cancer progression

2018

Cystatin C (Cyst C) is an endogenous inhibitor of lysosomal cysteine proteinases, which has been shown to play a role in several normal and pathological processes. Interestingly, a growing number of experimental and clinical studies suggest that this inhibitor also appears to be implicated in the malignant progression of various human tumors. However, the role of Cyst C in malignant diseases is still controversial as these studies have highlighted that this protein may function either as tumor suppressor or tumor promoter. The specific mechanisms underlying these opposing effects at present remain murky and are the subject of many current investigations. On the other hand, a complete knowle…

0301 basic medicineMetastasiCysteine proteinaseGeneral Biochemistry Genetics and Molecular BiologyCysteine Proteinase Inhibitorslaw.inventionMetastasisCathepsin03 medical and health sciences0302 clinical medicinelawNeoplasmsMedicineAnimalsHumansCystGeneral Pharmacology Toxicology and PharmaceuticsNeoplasm MetastasisCystatin CCancerCathepsinbiologybusiness.industryCancerProteinase inhibitorsGeneral Medicinemedicine.disease030104 developmental biologyCystatin C030220 oncology & carcinogenesisCancer researchbiology.proteinDisease ProgressionSettore BIO/14 - FarmacologiaSuppressorbusinessFunction (biology)
researchProduct

IL-34–Dependent Intrarenal and Systemic Mechanisms Promote Lupus Nephritis in MRL-Faslpr Mice

2019

Background In people with SLE and in the MRL- Fas lpr lupus mouse model, macrophages and autoantibodies are central to lupus nephritis. IL-34 mediates macrophage survival and proliferation, is expressed by tubular epithelial cells (TECs), and binds to the cFMS receptor on macrophages and to a newly identified second receptor, PTPRZ. Methods To investigate whether IL-34–dependent intrarenal and systemic mechanisms promote lupus nephritis, we compared lupus nephritis and systemic illness in MRL- Fas lpr mice expressing IL-34 and IL-34 knockout (KO) MRL- Fas lpr mice. We also assessed expression of IL-34 and the cFMS and PTPRZ receptors in patients with lupus nephritis. Results Intrarenal IL-3…

0301 basic medicineMice Inbred MRL lprChemokineCell SurvivalLupus nephritisRisk AssessmentMonocytesMice03 medical and health sciences0302 clinical medicineSpecies Specificityimmune system diseasesmedicineAnimalsMacrophageMolecular Targeted Therapyskin and connective tissue diseasesCells CulturedCell ProliferationMice KnockoutSystemic lupus erythematosusCell Deathbiologybusiness.industryInterleukinsMacrophagesGeneral MedicineMonocyte proliferationmedicine.diseaseLupus NephritisMice Inbred C57BLDisease Models AnimalBasic ResearchKidney Tubules030104 developmental biologyGene Expression RegulationNephrology030220 oncology & carcinogenesisImmunologyKnockout mouseDisease Progressionbiology.proteinChemokinesbusinessMacrophage proliferationNephritisJournal of the American Society of Nephrology
researchProduct

Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticular cancer therapy.

2016

Macrophages, myeloid-derived suppressor cells and tolerogenic dendritic cells are central players of a heterogeneous myeloid cell population, with the ability to suppress innate and adaptive immune responses and thus to promote tumor growth. Their influx and local proliferation are mainly induced by the cancers themselves, and their numbers in the tumor microenvironment and the peripheral blood correlate with decreased survival. Therapeutic targeting these innate immune cells, either aiming at their elimination or polarization toward tumor suppressive cells is an attractive novel approach to control tumor progression and block metastasis. We review the current understanding of cancer immun…

0301 basic medicineMyeloidPolymersmedicine.medical_treatmentPopulationBiomedical EngineeringMedicine (miscellaneous)BioengineeringDevelopmentBiology03 medical and health sciences0302 clinical medicineImmune systemNeoplasmsmedicineTumor MicroenvironmentAnimalsHumansGeneral Materials ScienceMyeloid CellsRNA Small InterferingeducationCancer immunologyeducation.field_of_studyTumor microenvironmentDrug CarriersInnate immune systemMacrophagesMyeloid-Derived Suppressor CellsImmunotherapyDendritic CellsImmunity Innate030104 developmental biologymedicine.anatomical_structureTumor progression030220 oncology & carcinogenesisImmunologyNanoparticlesImmunotherapyNanomedicine (London, England)
researchProduct

ASO Author Reflections: How Long will We Perform Lymphadenectomy in Endometrial Cancer Patients?

2022

Abstract Objectives To compare survival and progression outcomes between 2 nodal assessment approaches in patients with nonbulky stage IIIC endometrial cancer (EC). Methods Patients with stage IIIC EC treated at 2 institutions were retrospectively identified. At 1 institution, a historical series (2004–2008) was treated with systematic pelvic and para-aortic lymphadenectomy (LND cohort). At the other institution, more contemporary patients (2006–2013) were treated using a sentinel lymph node algorithm (SLN cohort). Outcomes (hazard ratios [HRs]) within the first 5 years after surgery were compared between cohorts using Cox models adjusted for type of adjuvant therapy. Results The study incl…

0301 basic medicineN.A.medicine.medical_specialtymedicine.medical_treatmentSentinel lymph nodeMEDLINEArticleEndometrial CancerDisease-Free Survival03 medical and health sciences0302 clinical medicineLymphadenectomy Endometrial CancerSurgical oncologyAdjuvant therapymedicineHumansStage IIICNeoplasm InvasivenessProgression-free survivalLymph nodeAgedNeoplasm StagingRetrospective Studiesbusiness.industryEndometrial cancerGeneral surgeryObstetrics and GynecologyLymphadenectomymedicine.diseaseEndometrial Neoplasms030104 developmental biologymedicine.anatomical_structureTreatment OutcomeSettore MED/40 - GINECOLOGIA E OSTETRICIASentinel nodeOncology030220 oncology & carcinogenesisLymphatic MetastasisDisease ProgressionLymph Node ExcisionFemaleSurgeryLymphadenectomySentinel Lymph NodebusinessAlgorithmChemoradiotherapyAlgorithmsAnnals of Surgical Oncology
researchProduct

A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival

2016

AbstractMultiple myeloma (MM) is closely dependent on cross-talk between malignant plasma cells and cellular components of the inflammatory/immunosuppressive bone marrow milieu, which promotes disease progression, drug resistance, neo-angiogenesis, bone destruction and immune-impairment. We investigated the relevance of inflammatory genes in predicting disease evolution and patient survival. A bioinformatics study by Ingenuity Pathway Analysis on gene expression profiling dataset of monoclonal gammopathy of undetermined significance, smoldering and symptomatic-MM, identified inflammatory and cytokine/chemokine pathways as the most progressively affected during disease evolution. We then sel…

0301 basic medicineOncologyAdultMaleCandidate genemedicine.medical_specialtyBiologyIFNCCL503 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansMultiple myelomaAgedAged 80 and overInflammationHematologyComputational BiologyHematologyMiddle Agedmedicine.diseaseNeoplasm ProteinsGene expression profilingGene Expression Regulation Neoplasticmyeloma030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisImmunologygene expressionDisease ProgressionOriginal ArticleFemaleIL17ABone marrowMultiple MyelomaTranscriptomeMonoclonal gammopathy of undetermined significanceSignal TransductionBlood Cancer Journal
researchProduct